Background: To identify whether RET is a potential target for NSCLC treatment, we examined the status of the RET gene in 631 early and mid stage NSCLC cases from south central China. Methods: RET expression was identified by Western blot. RET-positive expression samples were verified by immunohistochemistry. RET gene mutation, copy number variation, and rearrangement were analyzed by DNA Sanger sequencing, TaqMan copy number assays, and reverse transcription-PCR. ALK and ROS1 expression levels were tested by Western blot and EGFR mutation using Sanger sequencing. Results: The RET-positive rate was 2.5% (16/631). RET-positive expression was related to poorer tumor differentiation (P < 0.05). In the 16 RET-positive samples, only two samples of moderately and poorly differentiated lung adenocarcinomas displayed RET rearrangement, both in RET-KIF5B fusion partners. Neither ALK nor ROS1 translocation was found. The EGFR mutation rate in RET-positive samples was significantly lower than in RET-negative samples (P < 0.05). Conclusion: RET-positive expression in early and mid stage NSCLC cases from south central China is relatively low and is related to poorer tumor differentiation. RET gene alterations (copy number gain and rearrangement) exist in all RET-positive samples. RET-positive expression is a relatively independent factor in NSCLC patients, which indicates that the RET gene may be a novel target site for personalized treatment of NSCLC.
Introduction
Non-small cell lung cancer (NSCLC), which accounts for 80-85% of all lung cancer cases, has one of the highest cancer incidences in the world. 1, 2 It is usually diagnosed at an advanced stage and has a dismal prognosis. 2 NSCLC is further divided into subtypes based on histology and approximately 30% of cases are squamous cell carcinoma. The remaining 70% are classified as non-squamous NSCLC, which includes adenocarcinomas, large-cell carcinomas, and less well-differentiated tumors. 1, 3 Several key genetic alterations have been found in lung cancer, such as EGFR mutations and ALK rearrangement. [4] [5] [6] [7] The application of EGFR-tyrosine kinase inhibitors (TKIs) has highlighted the importance of targeted therapeutic agents to appropriate patient populations with specific genetic alterations. 8, 9 In addition, gene rearrangements, such as ALK and ROS1 have also been identified in NSCLC; tumors with ALK and ROS1 rearrangement are responsive to ALK-TKIs. 10 Although TKIs are effective for NSCLCs with corresponding gene mutations or rearrangements, the long-term efficacy is not satisfactory because of drug resistance. 4, 5 21 exons with a total length of about 60 000 bp. 12 The protein encoded by RET is a tyrosine kinase receptor, which binds to the ligand and stimulates intracellular phosphorylation, which in turn activates downstream signals and plays a critical role in proliferation, neuronal navigation, and differentiation. 13, 14 In NSCLC, the most common RET fusion pattern is with KIF5B. 15, 16 The first 15 exons of KIF5B containing kinesin motor and coiled-coil domains are rearranged to exons 12-20 of the RET gene, which contains the RET kinase domain. This rearrangement produces adverse activation of RET with homodimerization underlying the oncogenic potency of the gene fusion product. 15, 16 RET mutations are present in nearly all hereditary medullary thyroid cancer patients, and approximately 30% with RET gene copy number alteration are associated with poor outcomes. 17 Therefore, RET copy number alteration is a vital gene alteration in malignant tumors.
In this study, we examined the status of the RET gene in 631 early and mid stage NSCLC cases from south central China to identify whether RET is a potential target for NSCLC treatment.
Methods
We identified RET expression in all samples using Western blot. We then analyzed RET gene mutation, copy number variation, and rearrangement in RET-positive expression samples using DNA Sanger sequencing, TaqMan copy number assays, and reverse transcription (RT)-PCR. ALK and ROS1 expression was detected by Western blot and EGFR mutation by exon sequencing.
Sample and clinical data of non-small cell lung cancer patients NSCLC samples (n = 631, 466 men, 165 women; age range 21-84) and normal tissues (> 5 cm away from the tumor edge) were consecutively collected from patients by pulmonary lobectomy at the second Xiangya Hospital (Changsha, Hunan, China) from July 2008 to July 2014. All patients signed written consent and the hospital institutional review board approved the study. All patients were from south central China and were classified according to the World Health Organization classification system.
RET protein expression by Western blot
Frozen lung tumors and normal tissues (control) were minced in liquid nitrogen and resuspended in 1 × cell lysis buffer (10X #9803; Cell Signaling Technology, Danvers, MA, USA). Tissue suspension was then sonicated and cleared by centrifugation. RET protein immunoblot analysis was carried out according to the RET antibody (#3223, 1:1000; Cell Signaling Technology) following the manufacturer's standard protocol. A high RET expression sample confirmed with RET rearrangement by sequencing and a RET-positive papillary thyroid carcinoma sample identified by our hospital pathologist were used as positive control samples in immunoblot screening analysis.
Immunohistochemical staining
Immunohistochemical staining for RET was characterized by RET antibody (#ab134100, 1:200, monoclonal antibody; Abcam, Cambridge, MA, USA). Five-micrometer tissue sections of RET positive and negative lung tumor samples obtained by Western immunoblotting and two RETpositive papillary thyroid carcinoma samples identified by our hospital pathologist as control samples were deparaffinized, rehydrated, and subjected to antigen retrieval at high temperature and high pressure. Slides were quenched in 3% H 2 O 2 for 10 minutes, washed in diH 2 O, and then blocked with tris-buffered saline/0.1% Tween 20/5% goat serum. Slides were incubated overnight at 4 C with RET antibody. Immunohistochemical (IHC) detection was conducted using an UltraSensitive SP IHC Kit (Fuzhou Maixin Biotech, Fuzhou, China). All slides were exposed to an AEC Kit (Fuzhou Maixin Biotech, China) and counterstained with hematoxylin. Images (×20) were acquired using a Leica Light microscope (Leica Microsystems, Wetzlar, Germany) at high magnification and five horizons were randomly selected for immunochemical evaluation of RET. RET expression levels were scored from 0 to 2+ (0 for no staining, 0.5+ for weak, 1+ for moderate, and 2+ for strong immunoreactivity). The percentages of cells with positive RET staining within the cancerous region of a section were scored as follows: 0 for < 5% positive cells, 0.5 + for 5-10%, 1+ for 11-50%, and 2+ for 51-100%.
RET hot-point mutation analysis and reverse transcription-PCR of RET fusion
To analyze RET mutation, genomic DNA was extracted from frozen tumor tissues with positive RET protein expression using a Genomic DNA Purification Kit (Thermo Fisher Scientific, Waltham, MA, USA). Extracted DNA was analyzed by PCR, followed by direct sequencing, as previously described. 18 Further analysis was performed on the exons that were more frequently mutated (exons 8, 10, 11, 13-16). 19 The RET fusion variants of RET-positive expression samples were determined by RT-PCR using an RNA UltraSense One-step RT-PCR Kit (Life Technologies, Carlsbad, CA, USA) according to the product manual. The KIF5B primers used were: forward (5 0 -ATTAGGTGG CAACTGTAGAACC-3 0 ) and reverse 5 0 -CAGGCCCCATA-CAATTTGAT-3 0 .
RET gene copy number analysis 
Statistical analysis
Statistical analyses were performed using SPSS version 18.0 (SPSS Inc., Chicago, IL, USA). Continuous variables were expressed as mean AE standard deviation. Relationships between RET expression and clinicopathologic variables were examined using chi-square tests and correlation analysis. Results were considered statistically significant at P < 0.05.
Results

Patient characteristics
The clinicopathologic data of 631 (466 men, 165 women) early and mid stage NSCLC patients were obtained from medical records. The mean age (AE standard deviation) of the patients was 57.8 AE 9.57 (range 21-84). The tumor types were: squamous carcinomas (311), adenocarcinomas (287), adenosquamous carcinomas (21) , and other NSCLCs (12) ( Table 1) .
RET expression and immunohistochemical staining
We detected RET expression using Western blot (Fig 1) . As shown in Table 1 , among the 631 early and mid stage NSCLC samples, only 16 displayed positive RET expression, at a rate of 2.5% (16/631). The RET-positive samples were verified by IHC staining. IHC results showed that nine samples were strong positive (++), five were moderate immunoreactivity positive (+), and the remaining two were weak positive (0.5+) and negative (−) (Fig 2) . The results of IHC staining of lung cancer tissues corresponded to the Western blot results. Correlation analysis showed that positive RET expression was significantly related to poorer tumor differentiation (P < 0.05). There was no correlation between RET expression and age, gender, stage, Brinkman index, or histology classification (Table 1) .
RET alterations in RET-positive samples
After detecting positive RET expression in the NSCLC samples, we investigated the potential mechanisms underlying such expression. We first analyzed gene mutation on hot-point exons in RET-positive samples using a Genomic DNA Purification Kit (Thermo Fisher Scientific, USA). However, no RET gene mutations on hot-point exons 8, 10, 11, or 13-16 were detected in the 16 RET-positive samples. In order to explore the specific mechanism of RET expression in NSCLC, we detected RET fusion and RET copy number variants in the 16 RET-positive samples.
RT-PCR rearrangement testing showed that only two samples of moderately and poorly differentiated lung adenocarcinomas displayed RET rearrangement, both in RET-KIF5B fusion partners. The IHC results were strong positive (++). We then investigated RET gene copy number alteration in exons 4 and 8 and intron 13 in the remaining 14 samples. All 14 RET-positive samples showed RET copy number gain compared to the normal tissues and the five RET-negative expression samples (Fig 3) . These results showed that all RET-positive tumor samples presented rearrangement or copy number gain of the RET gene.
ALK and ROS1 expression and EGFR mutation in RET-positive samples
To identify an association between RET expression and ALK and ROS1 translocation and EGFR mutation, an analysis of ALK and ROS1 protein expression in the 16 RET-positive samples was conducted by immunoblotting. Neither ALK nor ROS1 translocation was found in the 16 RET-positive samples, while one EGFR mutation in exon 21 (L858R) was detected. We randomly selected 44 RET-negative expression samples for EGFR exon sequencing. As Table 2 shows, we found nine samples with EGFR exon 21 mutations (L858R) and six with EGFR exon 19 deletions. The EGFR mutation rate in RET-positive samples was significantly lower than in RET-negative samples (P < 0.05). These results indicate that ALK or ROS1 translocation or EGFR mutation rarely occurs in RET-positive patients. Therefore, RET gene alteration could be a potential target for NSCLC patients without such mutations.
Discussion
After decades of efforts to improve cancer therapy, targeted therapies and personalized medicine have become a new direction for cancer treatment. 6 Targeted therapies can be directed at unique molecular or gene products of cancer cells to produce greater efficacy of cancer treatment with less toxicity. Therefore, it is vital to identify effective tumor markers as the targets for cancer treatment to improve patient survival rates and quality of life in recurrent or advanced-stage malignant tumors.
NSCLC has one of the highest incidences of cancer globally and causes the highest rate of cancer-related death. During the past decades, targeted drugs, such as EGFR and ALK TKIs have been developed and have shown good therapeutic effects. 20, 21 Although several genetic mutations have previously been reported, no cancer genome mutation has been observed in a large proportion of NSCLC patients. More than 40% of NSCLCs appear to be driven by unknown genetic events; 22, 23 therefore, it is important to identify new biomarkers that can stratify NSCLC patients and acquire a better response to targeted therapy.
The oncogenic effect of RET was first identified in papillary thyroid cancer, where diverse kinds of chromosomal translocations and inversions led to the formation of papillary thyroid cancer/RET fusion genes. 24 Specific point mutations have also been reported as drivers in MEN2A and MEN2B. 24 In addition, activated RET has been observed in prostate 25 and pancreatic cancers 26 and melanoma. 27 The direct transforming impact of RET as a driver is also supported by transgenic mice studies of RET, which generated a variety of malignancies. 28, 29 A new RET gene fusion with KIF5B was first identified in lung cancer in 2012. 15 RET proto-oncogene expression increased with KIF5B fusion. RET rearrangement at a frequency of 1-2% has been reported. 29, 30 Drugs targeted to the RET gene inhibit RET kinase, the expression product of RET. Taking this into account, we first tested RET expression by Western blot in 631 NSCLC samples. Only 16 samples displayed positive RET expression at a rate of 2.5% (16/631). A retrospective analysis conducted by Platt et al. yielded an RET expression rate of 11.6% (40/346) in Asians, 31 which is much higher than our result. Differences in tumor staging may have caused our lower RET expression rate. Almost all of the patients in our study were at stages lower than IIB and surgery was indicated, whereas the patients in the 32 The reason for the lower RET translocation rate (2/631) and copy number gain in our study may be that we only examined RET gene alterations in RET-positive samples. The samples with RET-negative expression were not examined for gene alterations, and may have contained RET alterations. The differences between test methods, geography, and ethnicity may also have contributed to the differing results.
Tumors with ALK and ROS1 rearrangement are responsive to ALK-TKIs; however no ALK or ROS1 expression was found in the 16 samples in our study. Only one EGFR mutation in exon 21 (L858R) was detected. Thus, we randomly selected 44 RET-negative NSCLC samples for EGFR exon sequencing. We found nine samples with EGFR exon 21 mutations (L858R) and six with EGFR exon 19 deletions. Our EGFR mutation result of 26.7% (16/60) with both RET negative and positive samples is higher than the 19% (19/99) reported by Yang et al. 32 However, only one (6.25%) EGFR mutation was found in the RET-positive samples. This result indicates that targeted drugs for ALK, ROS1, or EGFR mutations may be not effective for RETpositive tumors. Only drugs with activity against RET kinase could be effective to these tumors. Recently, Kodama et al. demonstrated the antitumor activity of alectinib against RET-rearranged NSCLC. 33 Alectinib inhibited RET kinase and the growth of RET fusion-positive cells. However, alectinib has low activity against ROS1 kinase.
34
Although the RET expression rate is relatively low in early and mid stage NSCLC samples, ALK, ROS1, or EGFR mutations rarely occur in RET-positive patients. Targeted drugs are effective for RET-positive NSCLC.
The RET-positive expression rate is relatively low at early and mid stage NSCLC in patients from south central China. RET gene alterations (copy number gain and rearrangement) exist in all RET-positive samples. RET-positive expression is a relatively independent factor in NSCLC patients, which indicates that the RET gene may be a novel target site for personalized treatment of NSCLC.
